A Randomized, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of 5-day Azacitidine for Patients With Lower-risk Myelodysplastic Syndrome
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 23 Nov 2015 Planned End Date changed from 1 Aug 2014 to 1 Dec 2016.
- 23 Nov 2015 Planned primary completion date changed to 1 Jun 2016.
- 06 Aug 2012 New trial record